BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30430883)

  • 41. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
    Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GnRH agonist versus GnRH antagonist in ovarian stimulation: is the emperor naked?
    Orvieto R; Rabinson J; Meltzer S; Homburg R; Anteby E; Zohav E
    Clin Exp Obstet Gynecol; 2006; 33(4):197-9. PubMed ID: 17211964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of gonadotropin releasing hormone agonist long protocol and gonadotropin releasing hormone antagonist protocol in infertile women].
    Ren Y; Yang S; Yang R; Li R; Chen XN; Wang HY; Ma CH; Liu P; Qiao J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):877-81. PubMed ID: 24343066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frozen-thawed cleavage-stage embryo transfer cycles after previous GnRH agonist or antagonist stimulation.
    Bahçeci M; Ulug U; Erden HF; Tosun S; Ciray N
    Reprod Biomed Online; 2009 Jan; 18(1):67-72. PubMed ID: 19146771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET].
    Sun Y; Zhu YM
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 May; 38(3):305-10. PubMed ID: 19504641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
    Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
    Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
    Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
    Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the efficacy of depot GnRH agonist protocol and the GnRH antagonist protocol in patients with repeated IVF failure: a retrospective cohort study.
    Li T; Liu X; Yang X; Wang N; Wang Y; Li W; Liang X; Huang R
    Hum Fertil (Camb); 2023 Dec; 26(5):1299-1306. PubMed ID: 36946058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
    Olgan S; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
    Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
    Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.
    Dietrich JE; Freis A; Beedgen F; von Horn K; Holschbach V; Liebscher J; Strowitzki T; Germeyer A
    Front Endocrinol (Lausanne); 2020; 11():246. PubMed ID: 32411093
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.